Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Puma Biotechnology Inc. Is Sinking Today

By Cory Renauer - May 10, 2018 at 1:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Nerlynx launch might not be progressing as well as it seems on the surface.

What happened

Shares of Puma Biotechnology Inc. (PBYI -0.18%), a cancer-focused biotech, are sinking following a first-quarter earnings report issued after the bell yesterday. By all accounts, it was a solid quarter for the company's first commercial-stage product, but concerns for Nerlynx's future pushed the stock down 17.3% as of 11:27 a.m. EDT on Thursday.

So what 

Puma Biotechnology's first marketed product has inspired some analysts to predict peak annual sales in excess of $1 billion, but there's a catch: Nerlynx is intended as a treatment to stop breast cancer from recurring following treatment with Herceptin. Breast cancer affects enough people worldwide to drive sales that high, but Puma still needs to prove the side effects its drug is known to cause won't prevent real-world patients from remaining on treatment for long periods. With this in mind, a 23.7% discontinuation rate so far from patients receiving their treatment from specialty pharmacies was troubling.

Person drawing a downward sloping chart.

Image source: Getty Images.

Puma was quick to point out plenty of benign situations that end up recorded as discontinuations, such as switching sources. Also, the rate of patients who stop therapy due to side effects has only been around 12% since the drug launched last July.

Now what

Lofty estimates for Nerlynx also include an eventual approval in the EU, but a negative committee opinion nearly dashed those hopes earlier this year. Puma expects to hear about a reexamination of that opinion in June or July.

Investors hoping for data from the 600-patient NALA trial with Nerlynx as a third-line breast cancer treatment will have to wait a while longer. The trial completed enrollment last July, but the rate of disease progression among patients has been slower than historical data suggested when the company promised speedier results.

If Nerlynx is causing the slower disease progression rate, the stock could recover some of its recent losses. Investigators will unblind the data once a certain number of progression events occur, probably in the fourth quarter.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Puma Biotechnology, Inc. Stock Quote
Puma Biotechnology, Inc.
$2.77 (-0.18%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.